ImmunoGenesis

ImmunoGenesis is targeting a critical unmet need in oncology: the majority of solid tumors are immune-excluded ('cold') and do not respond to first-generation PD-1/PD-L1 inhibitors. The company's core strategy involves engineering multifunctional, cytotoxic immune checkpoint inhibitors that combine best-in-class PD-1 pathway blockade with mechanisms to eliminate suppressive cells and reverse immunosuppressive barriers. Its lead asset, IMGS-001, is a first-in-class antibody designed to block both PD-L1 and PD-L2 while actively destroying tumor-protective cells, aiming to establish a new foundational monotherapy for cold tumors.

Rational design of multifunctional immunotherapies focusing on cytotoxic immune checkpoint inhibitors (block checkpoint and eliminate suppressive cells) and hypoxia-activated prodrugs to reverse immune exclusion in cold tumors.

ImmunoGenesis competes in the crowded immuno-oncology space against large pharma and biotechs also targeting cold tumors via various mechanisms (e.g., cancer vaccines, oncolytic viruses, other TME modulators). Its differentiation lies in its specific focus on multifunctional cytotoxic checkpoint blockade and hypoxia reversal as a direct attack on immune exclusion mechanisms.